A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 152 participants.

Also called NCT07064486

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 152 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07064486
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Indonesia (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT07064486. Randomized; no masking; primary purpose treatment. Start 2025-07-04 (actual); primary completion 2027-04-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia
Condition
Type 2 Diabetes (T2DM)
Intervention (Drug)
BGM0504
Intervention (Drug)
BGM0504
Intervention (Drug)
Semaglutide
Lead sponsor
BrightGene Bio-Medical Technology Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07064486
Content hash
5490f59f5a35fde62b545110f48745a1562b85f8570fdc1a3fcadb2060fe14a6